Treatment with anti-activin A antibody restored GH levels in Gr-1(+) cells and serum of EGFRdn mice and improved cardiac function, suggesting that normalizing the GH levels by inhibiting activin A is a novel therapeutic strategy for heart failure. This evidence concerns the gene GH1 and heart failure.